Travelan Experiences Strong Q1 FY2018 Sales Growth
November 08, 2017 09:00 ET
|
Immuron Limited
Key Highlights: Significant growth of sales for Immuron’s over-the-counter supplement Travelan® for Q1 2018 compared to Q1 2017 Travelan® US experienced a 197% increase in sales compared to Q1...
Immuron Commences US Non-Deal Institutional Investor Roadshow
August 15, 2017 09:15 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
August 09, 2017 08:30 ET
|
Immuron Limited
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...
Immuron Signs Shigella Vaccine Development Agreement with US Army
June 23, 2016 09:07 ET
|
Immuron Limited
MELBOURNE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has...